• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

    10/13/22 11:50:30 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care
    Get the next $CVET alert in real time by email
    SC 13D/A 1 d327384dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)*

     

     

    Covetrus, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    22304C100

    (CUSIP Number)

    CD&R VFC Holdings, L.P.

    c/o Clayton, Dubilier & Rice, LLC

    Attention: Rima Simson

    375 Park Avenue

    New York NY 10152

    (212) 407-5227

    with a copy to:

    Debevoise & Plimpton LLP

    Attention: Nicholas P. Pellicani, Esq.

    919 Third Avenue

    New York, NY 10022

    (212) 909-6000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    October 13, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box  ☐.

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 22304C100

     

      1.    

      NAME OF REPORTING PERSON

     

      CD&R VFC HOLDINGS, L.P.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC

      5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

       CAYMAN ISLANDS

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      SOLE VOTING POWER

     

      0 (see Item 5)

         8.   

      SHARED VOTING POWER

     

      0

         9.   

      SOLE DISPOSITIVE POWER

     

      0 (see Item 5)

       10.   

      SHARED DISPOSITIVE POWER

     

      0

    11.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0 (see Item 5)

    12.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0% (see Item 5)

    14.  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      PN

     

    2


    CUSIP No. 22304C100

     

      1.    

      NAME OF REPORTING PERSON

     

      CD&R INVESTMENT ASSOCIATES IX, LTD.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      SOURCE OF FUNDS (SEE INSTRUCTIONS)

     

      SC

      5.  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

     

      ☐

      6.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

       CAYMAN ISLANDS

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      SOLE VOTING POWER

     

      0 (see Item 5)

         8.   

      SHARED VOTING POWER

     

      0

         9.   

      SOLE DISPOSITIVE POWER

     

      0 (see Item 5)

       10.   

      SHARED DISPOSITIVE POWER

     

      0

    11.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      0

    12.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      0% (see Item 5)

    14.  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      CO

     

    3


    EXPLANATORY NOTE

    This Amendment No. 6 amends the Statement on Schedule 13D (“Schedule 13D”) initially filed on February 11, 2019 with the U.S. Securities and Exchange Commission and amended by Amendment No. 1 filed on May 1, 2020, Amendment No. 2 filed on May 20, 2020, Amendment No. 3 filed on November 20, 2020, Amendment No. 4 filed on May 20, 2022 and Amendment No. 5 filed on May 25, 2022 by (i) CD&R VFC Holdings, L.P., a Cayman Islands exempted limited partnership (“CD&R Holdings”), and (ii) CD&R Investment Associates IX, Ltd., a Cayman Islands exempted company (“CD&R Holdings GP” and, together with CD&R Holdings, the “Reporting Persons”).

    ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

    Item 3 of the Schedule 13D is hereby supplemented to incorporate by reference the information set forth in Item 4 below.

    ITEM 4. PURPOSE OF TRANSACTION.

    Item 4 of the Schedule 13D is hereby supplemented to include the following information:

    Merger Closing

    On October 13, 2022, Covetrus, Inc. (the “Issuer”), Corgi Bidco, Inc. (“Parent”) and Corgi Merger Sub, Inc. (“Merger Sub”) completed the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 24, 2022 (the “Merger Agreement”), by and among the Issuer, Parent and Merger Sub. Pursuant to the Merger Agreement, Merger Sub merged with and into the Issuer (the “Merger”), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent (the “Surviving Corporation”). Immediately prior to the Merger, CD&R Holdings contributed all of its Shares (as defined below) to a parent entity of Parent (with such Shares subsequently contributed to Parent) pursuant to the Support and Rollover Agreement (the “Contribution”). As a result of the Contribution and the Merger, the Reporting Persons and investment funds (other than the Reporting Persons) associated with Clayton, Dubilier & Rice, LLC and TPG Global, LLC became the indirect owners of all of the issued and outstanding shares of common stock of the Surviving Corporation.

    At the effective time of the Merger (the “Effective Time”), in accordance with the terms and conditions set forth in the Merger Agreement, each share of the Issuer’s common stock, par value $0.01 per share (the “Shares”), outstanding immediately prior to the Effective Time (other than Shares owned by (i) Parent or Merger Sub or any of their respective subsidiaries (including the Shares indirectly transferred by CD&R Holdings to Parent as part of the Contribution), (ii) the Issuer as treasury stock (the Shares referred to in (i) and (ii), the “Excluded Shares”) and (iii) Issuer stockholders (the “Dissenting Stockholders”) who had perfected and not withdrawn a demand for appraisal rights in accordance with Section 262 of the Delaware General Corporation Law (the “DGCL”)), was converted into the right to receive cash in an amount equal to $21.00 per share, without interest and subject to any required withholding taxes (the “Merger Consideration”). At the Effective Time, the Excluded Shares were cancelled and ceased to exist without payment of any consideration therefor and Dissenting Stockholders became entitled to receive only the payment provided by Section 262 of the DGCL with respect to Shares owned by such Dissenting Stockholder, provided that if, after the Effective Time, any person who otherwise would be deemed a Dissenting Stockholder shall have failed to properly perfect or shall have effectively withdrawn or lost the right to dissent under Section 262 of the DGCL or if a court of competent jurisdiction shall finally determine that the Dissenting Stockholder is not entitled to relief provided by Section 262 of the DGCL with respect to any Shares, such Shares shall thereupon be treated as though such Shares had been converted, as of the Effective Time, into the right to receive the Merger Consideration without interest and less any required tax withholding. Merger Consideration was funded by Parent through $1,905 million of debt financing, provided by the Debt Financing Sources, and $1,604 million of equity financing, provided by the Guarantors pursuant to the Equity Commitment Letters.

     

    4


    On October 13, 2022, the Issuer notified the Nasdaq Global Select Market (“NASDAQ”) that the Merger had been completed, and requested that NASDAQ suspend trading of Shares on NASDAQ prior to the opening of trading on October 13, 2022. The Issuer also requested that NASDAQ file with the U.S. Securities and Exchange Commission (the “SEC”) a notification of removal from listing and registration on Form 25 to effect the delisting of all Shares from NASDAQ and the deregistration of such shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As a result, Shares will no longer be listed on NASDAQ.

    In addition, the Issuer intends to file a certification on Form 15 with the SEC requesting the termination of registration of all Shares under Section 12(g) of the Exchange Act and the suspension of the Issuer’s reporting obligations under Section 13 of the Exchange Act with respect to all Shares.

    Changes to Board of Directors and Officers

    At, and conditioned on the occurrence of, the Effective Time, Deborah G. Ellinger, Paul Fonteyne, Sandra L. Helton, Philip A. Laskawy, Mark J. Manoff, Edward M. McNamara, Steven Paladino, Sandra Peterson, Ravi Sachdev and Sharon Wienbar each resigned from their positions as members of the board of directors of the Issuer and from any and all committees of the board of directors on which they served. Pursuant to the terms of the Merger Agreement, at the Effective Time, Benjamin Wolin and Matthew J. Foulston, who were directors of Merger Sub immediately before the Effective Time, were elected as the directors of the Surviving Corporation. The officers of the Issuer immediately prior to the Effective Time continued as officers of the Surviving Corporation.

    Amendments to Articles of Incorporation of Bylaws

    Pursuant to the terms of the Merger Agreement, at the Effective Time, the Issuer’s Second Amended and Restated Certificate of Incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety.

    Pursuant to the terms of the Merger Agreement, at the Effective Time, the Issuer’s Amended and Restated Bylaws, as in effect immediately prior to the Effective Time, was amended and restated in their entirety.

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

    (a)-(b) As of the date hereof, following the Contribution and the Merger, the Reporting Persons did not directly hold any Shares. Through their indirect interests in Parent, the Reporting Persons may be deemed to beneficially own and share the power to vote and dispose of shares of common stock of the Surviving Corporation.

    (c) Except as otherwise described in Item 4 of this Schedule 13D, each of the Reporting Persons reports that neither it, nor to its knowledge, any other person named in Schedule A of this Schedule 13D, has effected any transactions in Shares in the past 60 days.

    (d) None of the Reporting Persons has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares.

    (e) On October 13, 2022, each of the Reporting Persons ceased to be the beneficial owners of more than 5% of the outstanding Shares.

     

    5


    ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

    Item 6 of the Schedule 13D is hereby supplemented to incorporate by reference the information set forth in Item 4 above.

     

    6


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: October 13, 2022

     

    CD&R VFC HOLDINGS, L.P.
      By:   CD&R Investment Associates IX, Ltd.,
        its general partner
             By:  

    /s/ Rima Simson

          Name: Rima Simson
          Title: Vice President, Treasurer and Secretary
    CD&R INVESTMENT ASSOCIATES IX, LTD.
        By:  

    /s/ Rima Simson

          Name: Rima Simson
          Title: Vice President, Treasurer and Secretary

     

    7

    Get the next $CVET alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CVET

    DatePrice TargetRatingAnalyst
    6/13/2022$22.00Buy → Hold
    Stifel
    5/23/2022Outperform → Mkt Perform
    Raymond James
    11/18/2021$19.00Equal-Weight
    Morgan Stanley
    11/5/2021$37.00 → $27.00Outperform
    Raymond James
    8/9/2021$46.00 → $38.00Overweight
    Barclays
    8/6/2021$38.00 → $37.00Outperform
    Raymond James
    8/5/2021$29.00Neutral
    Credit Suisse
    7/12/2021$30.00Neutral → Buy
    Guggenheim
    More analyst ratings

    $CVET
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

      Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

      8/8/24 9:00:00 AM ET
      $SEMR
      $CVET
      Computer Software: Prepackaged Software
      Technology
      Other Pharmaceuticals
      Health Care
    • Westlake Set to Join S&P MidCap 400; MillerKnoll to Join S&P SmallCap 600

      NEW YORK, Oct. 13, 2022 /PRNewswire/ -- Westlake Corp. (NYSE:WLK) will replace MillerKnoll Inc. (NASD:MLKN) in the S&P MidCap 400, and MillerKnoll will replace Covetrus Inc. (NASD:CVET) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 18. Clayton, Dubilier & Rice and TPG Capital acquired Covetrus in a deal that closed today. MillerKnoll is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 18, 2022 S&P MidCap 400 Addition Westlake WLK Materials S&P MidCap 400 Deletion Miller

      10/13/22 5:50:00 PM ET
      $CVET
      $MLKN
      $SPGI
      $WLK
      Other Pharmaceuticals
      Health Care
      Office Equipment/Supplies/Services
      Consumer Discretionary
    • Covetrus Names Michelle Bonfilio as Chief People Officer

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

      9/26/22 4:00:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Leadership Updates

    Live Leadership Updates

    See more
    • Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

      Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

      8/8/24 9:00:00 AM ET
      $SEMR
      $CVET
      Computer Software: Prepackaged Software
      Technology
      Other Pharmaceuticals
      Health Care
    • Covetrus Names Michelle Bonfilio as Chief People Officer

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

      9/26/22 4:00:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Names Margie B. Pritchard General Counsel

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben Wolin, President and Chief Executive Officer (CEO) at Covetrus. Prior to being named as General Counsel, Pritchard most recently served as Vice President, Deputy Counsel at Covetrus, where she was responsible for corporate and board governance, public reporting, advising investor relations, employment matters including compensation, and providing general legal counsel to executive management. "Margie has been serving as Interim General Counsel since December 2021, and we are thrilled to have h

      8/26/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

      SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

      10/13/22 11:50:30 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

      SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

      5/25/22 12:15:30 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

      SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

      5/20/22 8:00:28 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cd&R Investment Associates Ix, Ltd. disposed of 33,670,541 shares

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:44:56 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Helton Sandra L returned 38,095 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:08:02 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Laskawy Philip A returned 15,064 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:07:42 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Covetrus downgraded by Stifel with a new price target

      Stifel downgraded Covetrus from Buy to Hold and set a new price target of $22.00

      6/13/22 7:15:59 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus downgraded by Raymond James

      Raymond James downgraded Covetrus from Outperform to Mkt Perform

      5/23/22 7:13:08 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Morgan Stanley initiated coverage on Covetrus with a new price target

      Morgan Stanley initiated coverage of Covetrus with a rating of Equal-Weight and set a new price target of $19.00

      11/18/21 8:28:56 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    SEC Filings

    See more
    • SEC Form 15-12G filed by Covetrus Inc.

      15-12G - COVETRUS, INC. (0001752836) (Filer)

      10/24/22 11:12:59 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Covetrus Inc.

      S-8 POS - COVETRUS, INC. (0001752836) (Filer)

      10/13/22 11:19:58 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13E3/A filed by Covetrus Inc. (Amendment)

      SC 13E3/A - COVETRUS, INC. (0001752836) (Subject)

      10/13/22 11:17:50 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    $CVET
    Financials

    Live finance-specific insights

    See more
    • Covetrus Announces Financial Results for Second Quarter of 2022

      Second quarter 2022 net sales of $1.22 billion, an increase of 2% year-over-year; GAAP net loss attributable to Covetrus of $(4) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA was flat year-over-year at $66 million, including a $2 million year-over-year headwind from the strengthening of the U.S. Dollar First half 2022 net sales of $2.37 billion, an increase of 3% year-over-year; GAAP net loss attributable to Covetrus of $(6) million Non-GAAP organic net sales growth of 6% year-over-year Non-GAAP adjusted EBITDA increased 5% year-over-year to $129 million, including a $4 million year-over-year headwind from the strengthening of the U.S.

      8/4/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces First Quarter 2022 Earnings Release Date and Conference Call Information

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, announced today that it will release first quarter 2022 results after the market closes on Thursday, May 5, 2022. Following the release, the Company will hold a conference call at 4:30 PM ET, during which Ben Wolin, president and chief executive officer, and Matthew Foulston, executive vice president and chief financial officer, will review the results. To access the live webcast of the conference call and the corresponding slide presentation, individuals can register at our Investor Relations site: https://ir.covetrus.com/investors/events-and-presentations. An archived edition of the conference call will be

      4/29/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces Financial Results for Fourth Quarter and Full-Year of 2021

      Fourth quarter 2021 net sales of $1.12 billion, unchanged year-over-year; GAAP net loss attributable to Covetrus of $(3) million Non-GAAP organic net sales growth of 2% year-over-year Non-GAAP adjusted EBITDA increased 13% year-over-year to $63 million Full-year 2021 net sales of $4.58 billion, an increase of 5% year-over-year; GAAP net loss attributable to Covetrus of $(54) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA increased 8% year-over-year to $244 million 2022 non-GAAP organic net sales growth guidance of 7% to 8% and non-GAAP adjusted EBITDA guidance in the range of $270 million to $280 million Covetrus® (NASDAQ:CVET), a

      2/24/22 4:01:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care